# Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc. is a company headquartered in San Diego, CA, United States.

## Company overview

- **Legal name:** Poseida Therapeutics, Inc.
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** San Diego, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001661460

## About

Poseida Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001661460, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2024-03-07, it reported annual revenue of USD 64,703,000; net income of USD -123,430,000; total assets of USD 273,885,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $64.7M (USD 64,703,000)
- **Net income:** -$123.4M (USD -123,430,000)
- **Total assets:** $273.9M (USD 273,885,000)
- **Cash and equivalents:** $44.5M (USD 44,472,000)
- **Operating cash flow:** -$92.2M (USD -92,167,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $130.5M (USD 130,492,000)
- **Net income:** -$64.0M (USD -64,002,000)
- **Total assets:** $351.8M (USD 351,837,000)
- **Cash and equivalents:** $81.4M (USD 81,378,000)
- **Operating cash flow:** -$26.8M (USD -26,772,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $31.2M (USD 31,238,000)
- **Net income:** -$125.0M (USD -124,974,000)
- **Total assets:** $269.3M (USD 269,309,000)
- **Cash and equivalents:** $206.3M (USD 206,325,000)
- **Operating cash flow:** -$102.5M (USD -102,543,000)

### FY2020 (period ended 2020-12-31)

- **Net income:** -$129.8M (USD -129,775,000)
- **Total assets:** $371.5M (USD 371,484,000)
- **Cash and equivalents:** $84.0M (USD 83,966,000)
- **Operating cash flow:** -$113.3M (USD -113,328,000)

## Recent SEC filings

- Form 8-K — filed 2025-01-08 — period 2025-01-08 — 8-K
- Form 8-K — filed 2024-11-26 — period 2024-11-25 — 8-K
- Form 8-K — filed 2024-11-14 — period 2024-11-14 — 8-K
- Form SC 13G — filed 2024-11-08
- Form 10-Q — filed 2024-11-07 — period 2024-09-30 — 10-Q
- Form 8-K — filed 2024-11-07 — period 2024-11-07 — 8-K
- Form SC 13G — filed 2024-10-22
- Form 8-K — filed 2024-09-30 — period 2024-09-27 — 8-K
- Form 10-Q — filed 2024-08-05 — period 2024-06-30 — 10-Q
- Form 8-K — filed 2024-08-05 — period 2024-08-05 — 8-K
- Form 8-K — filed 2024-06-18 — period 2024-06-17 — 8-K
- Form 10-Q — filed 2024-05-14 — period 2024-03-31 — 10-Q

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/poseida-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology